secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001808805-25-000077
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M
--------------------------------------------------------------------------------

- Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.
- Operating expenses $15.5M, down 19% from $19.1M year-over-year.
- Cash and investments $168.5M as of Sept 30, 2025.
- Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/0001808805-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/naut-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001808805-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer